1 Widespread aberrant alternative splicing despite molecular

2 remission in chronic myeloid leukemia patients

3	Illf Schmitz ¹⁻³	Journich S. Shak	$2^{,3}$ B ijov D	Dhungal ^{2,3}	Geoffroy	Montouvie ²	D hue L oi L uu^4
5	UII SCIIIIIIZ,	Jaymsii S. Shai	i , Dijay I.	Diffunger,	Ocomay	monieuuis,	r nuc-Lor Luu,

- 4 Veronika Petrova¹, Cynthia Metierre², Shalima S. Nair^{5,6}, Charles G. Bailey^{2,3}, Verity A.
- 5 Saunders⁷, Ali G. Turhan⁸, Deborah L. White^{7,9-12}, Susan Branford^{9,11,13,14}, Susan Clark^{4,16},

6 Timothy P. Hughes^{9,10,14,15}, Justin J-L. Wong^{3,17}, John E.J. Rasko^{2,3,18}

¹Computational BioMedicine Laboratory Centenary Institute, The University of Sydney,

8 Australia; ²Gene & Stem Cell Therapy Program Centenary Institute, The University of

9 Sydney, Australia; ³Faculty of Medicine & Health, The University of Sydney, Australia;

⁴Epigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of

11 Medical Research, Sydney, Australia; ⁵Kinghorn Centre for Clinical Genomics Core Facility,

12 Garvan Institute of Medical Research, Sydney, Australia; ⁶St Vincent's Clinical School,

13 Faculty of Medicine, UNSW, Darlinghurst, Australia; ⁷Cancer Program, Precision Medicine

14 Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia;

⁸APHP, Division of Hematology, Paris Sud University Hospitals and Inserm U935

16 INGESTEM Pluripotent Stem Cell Infrastructure 78 Rue du Général Leclerc, 94275 Le

17 Kremlin Bicetre, France; ⁹School of Medicine, Faculty of Health and Medical Sciences,

18 University of Adelaide, Adelaide, SA, Australia; ¹⁰Australasian Leukaemia and Lymphoma

19 Group, Melbourne, VIC, Australia; ¹¹School of Biological Sciences, Faculty of Sciences,

20 University of Adelaide, Adelaide, Australia; ¹²South Australian Health and Medical Research

21 Institute, Adelaide, Australia; ¹³Department of Genetics and Molecular Pathology, Centre for

22 Cancer Biology, SA Pathology, Adelaide, Australia; ¹⁴School of Pharmacy and Medical

23 Science, Division of Health Sciences, University of South Australia, Adelaide, Australia; ¹⁵St

- 24 Vincent's Clinical School, UNSW, Sydney, Australia; ¹⁶Department of Haematology, Centre
- 25 for Cancer Biology, SA Pathology, Adelaide, Australia; ¹⁷Epigenetics and RNA Biology
- 26 Program Centenary Institute, The University of Sydney, Australia; ¹⁸Cell and Molecular
- 27 Therapies, Royal Prince Alfred Hospital, Camperdown, Australia

- 28
- 29 Correspondence: John E.J. Rasko, Locked Bag No. 6, Newtown 2042, NSW
- 30 Australia; e-mail: j.rasko@centenary.org.au; Tel: 02 95656160
- 31
- 32
- 33

34 Abstract

35	Background: Vast transcriptomics and epigenomics changes are characteristic of
36	human cancers including leukemia. At remission, we assume that these changes
37	normalise so that omics-profiles resemble those of healthy individuals. However, an
38	in-depth transcriptomic and epigenomic analysis of cancer remission has not been
39	undertaken. A striking exemplar of targeted remission induction occurs in chronic
40	myeloid leukemia (CML) following tyrosine kinase inhibitor (TKI) therapy.
41	Methods: Using RNA sequencing and whole-genome bisulfite sequencing, we
42	profiled samples from chronic-phase CML patients at diagnosis and remission, and
43	compared these to healthy donors.
44	Results: Remarkably, our analyses revealed that abnormal splicing distinguishes
45	remission samples from normal controls. This phenomenon is independent of the TKI
46	drug used and in striking contrast to the normalisation of gene expression and DNA
47	methylation patterns. Most remarkable are the high intron retention (IR) levels that
48	even exceed those observed in the diagnosis samples. Increased IR affects cell cycle
49	regulators at diagnosis and splicing regulators at remission. We show that aberrant
50	splicing in CML is associated with reduced expression of specific splicing factors,
51	histone modifications and reduced DNA methylation.
52	Conclusions: Our results provide novel insights into the changing transcriptomic and
53	epigenomic landscapes of CML patients during remission. The conceptually
54	unanticipated observation of widespread aberrant alternative splicing after remission
55	induction warrants further exploration. These results have broad implications for
56	studying CML relapse and treating minimal residual disease.
57	

58 Keywords: transcriptomic complexity, alternative splicing, intron retention, DNA
59 methylation, epigenetics, BCR-ABL1, histone modifications, CML, cancer

60

61 Background

62	Characterisation of	f BCR-ABL1	and its	constitutive	tyrosine	kinase	activity	has
-		-						

63 facilitated understanding of the pathogenesis and therapy of CML¹. Tyrosine kinase

64 inhibitor (TKI) treatment results in positive responses in 60-90% of patients with

65 chronic phase CML^{2,3}. However, molecular mechanisms that facilitate CML

66 maintenance and relapse remain elusive⁴. While the molecular causes of CML are

67 well understood, measures of therapy success based on BCR-ABL1 expression and

68 white blood cell count are not reliable predictors of relapse.

69 *BCR-ABL1* overexpression perturbs the hematopoietic transcriptome^{4,5}. CML

70 progression, maintenance, and therapy may be affected by aberrant expression and

alternative splicing of cancer-causing genes 6,7 . Alternative splicing is vital for cellular

72 homeostasis and dysregulated intron retention (IR) has been associated with

73 numerous human cancers including leukemia⁸. However, the role of alternative

74 splicing in CML remains unknown.

75 In addition to risk-associated genomic variants which predict poor outcome⁹, there is

respectively 76 evidence that epigenetic regulation affects CML pathology and therapy success¹⁰.

77 Epigenetic regulation via DNA methylation and nucleosome occupancy play key

roles in constitutive and alternative mRNA splicing regulation¹¹⁻¹³. Epigenetic

regulation via DNA methylation is known to regulate constitutive and alternative

80 mRNA splicing. To date, no systematic transcriptomics and epigenomics analyses in

81 CML remission samples have been conducted, neither have the effects of different

82 therapeutic regimens on gene expression and alternative splicing been assessed. CML

83	presents an excellent model to study epigenetically mediated transcriptomic
84	alterations in myeloid cells that cause malignant transformation and the response to
85	TKI treatment. New insights into this multilayered regulatory network could provide
86	important clues for targeted therapies used in other malignancies as well.
87	Here we report novel transcriptional and epigenetic patterns in a multi-omics analysis
88	of CML patient samples before and after effective front-line TKI treatment. Using this
89	model, we found abnormal splicing in chronic-phase CML patients, which we
90	confirmed in a larger independent cohort. Surprisingly, we also observed aberrant
91	splicing patterns in complete molecular remission. This is in contrast to the
92	normalisation of gene expression and DNA methylation patterns driven by the
93	reconfiguration of blood cell composition. More specifically, we observed a marked
94	increase in IR and differential exon usage in CML diagnosis and remission compared
95	to normal samples, as well as evidence that epigenetic factors modulate splicing in
96	CML.

97 Methods

- 98 Patient samples
- 99 We retrieved nine diagnostic specimens (total leukocytes from peripheral blood
- 100 collected in EDTA) from patients enrolled in the RESIST (1x imatinib;
- 101 ACTRN12610000055000), ENESTxtnd (4x nilotinib, NCT01254188) and
- 102 PINNACLE (4x nilotinib + pegylated interferon, ACTRN12612000851864) trials,
- 103 with matched remission specimens (major or complete molecular response at 12 or 24
- 104 months). In addition, eight CML patient samples (7 diagnostic and 1 matched
- 105 remission) from the French Persistem study were obtained. For the validation of IR
- 106 events and fusion transcripts we retrieved further matched diagnosis/remission
- 107 samples from the TIDELII trial (20x imatinib, ACTRN12607000325404). RNA was

- 108 isolated from mononuclear cells (from peripheral blood collected in LiHep) which
- 109 had been cryopreserved and subsequently thawed into TRIzol. All studies were
- approved by the institutional review boards (HREC protocol No: 131015, 070718c,
- 111 081211, and 101010 Royal Adelaide Hospital) and are in accordance with the
- 112 Declaration of Helsinki. Patients provided written informed consent.
- 113
- 114 RNA isolation and mRNA-seq
- 115 Total RNA was isolated from diagnosis, remission, and control samples (peripheral
- 116 blood mononuclear cells PBMCs) using Trizol according to the manufacturer's
- 117 protocol. For mRNA sequencing, poly-A enriched mRNA libraries were prepared
- 118 from 1 µg of total RNA using the TruSeq Stranded RNA sample prep kit (Illumina),
- 119 prior to paired-end sequencing using the HiSeq 2500 platform. RNA sequencing was
- 120 performed in triplicates for each sample. The raw sequencing data (fastq files) have
- 121 been deposited at GEO under accession GSE144119.
- 122
- 123 mRNA sequencing data analysis

124 Paired-end RNA-sequencing reads (125 nt) were trimmed and mapped to the human reference genome hg38 using STAR¹⁴. Quality control of raw and mapped sequencing 125 126 reads was performed using FASTOC (github.com/s-andrews/FastOC), RSeOC¹⁵, and 127 $multiqc^{16}$. Putative confounders and batch effects were excluded using principal components analyses (Supplementary Figure 1). STAR-FUSION¹⁷ was used for the 128 129 identification of fusion genes and Fusion Inspector (FusionInspector.github.io) for in 130 silico validation of the predicted gene fusions. Gene expression levels specified as transcripts per million (TPM) were determined using Salmon $0.14.1^{18}$. 131

132	General statistics on alternative splicing events were determined using the rMATS
133	software ¹⁹ . We used our IRFinder algorithm for the detection of IR events in introns
134	extracted from an Ensembl gtf file (regions between two adjacent exons) ²⁰ . IRFinder
135	estimates the abundance of IR by computing the ratio between gene transcripts
136	retaining an intron and the sum of all transcripts of the respective gene (more
137	information is provided in the Supplementary Materials).
138	Differentially used exons were determined using the R Bioconductor package
139	$DEXSeq^{21}$. Differential exon usage (DEU) = changes in the relative usage of exons:
	$transcripts_{with_exon}$ /($transcripts_{with_exon}$ + $transcripts_{without_exon}$)
140	
141	IR validation
142	Extracted RNA (2 μ g) was treated with DNAse Turbo (Invitrogen) and reverse
143	transcribed into cDNA using oligo(dT) priming and Superscript III (ThermoFisher)
144	according to the protocol supplied by the manufacturer. For each sample, a
145	corresponding control without reverse transcriptase was used to assess DNA
146	contamination. For qPCR, cDNA templates were amplified, and the C_t values were
147	quantified with SYBR Green Master Mix (ThermoFisher). Beta-2 microglobulin
148	(B2M) was used as the normalization control for cDNA input. Experiments were

- 149 performed using the CFX96 Real-Time PCR System (BIORAD). The list of primers
- 150 is provided in Supplementary Table 1.
- 151
- 152 Whole genome bisulfite sequencing (WGBS)
- 153 WGBS libraries were prepared following Illumina's "Whole- Genome Bisulfite
- sequencing for Methylation Analysis" protocol. Briefly, 1 µg of genomic DNA was
- spiked with 0.5% unmethylated lambda DNA and sonicated to generate fragments of

156	size between 150 to 300 bp. Library preparation was performed using Illumina's
157	Paired-end DNA Sample Prep Kit (discontinued, Illumina, CA, USA) according to
158	the manufacturer's protocol. The size-selected libraries were then subjected to
159	bisulfite conversion as previously described ²² . Adaptor-ligated bisulfite treated DNA
160	was enriched by 10 cycles of PCR amplification using the PfuTurbo Cx Hotstart DNA
161	Polymerase (Stratagene). Qualitative and quantitative checks of the libraries were
162	performed using Agilent's High sensitivity DNA kit (Agilent) and KAPA Library
163	quantification kit (KAPA Biosystems). Three lanes of paired-end 100 bp sequencing
164	was performed for each of the library on the Illumina HiSeq2500 platform using the
165	TruSeq v3 cluster kits and SBS kits to achieve coverage ranging between 25-30x.
166	
167	WGBS data analysis
168	Reads were processed and aligned to the human (hg38) reference genome using
169	Meth10X (github.com/luuloi/Meth10X) ²³ . In short, the Meth10X pipeline takes raw
170	reads in fastq format and trims the adaptors, which are then aligned to the human
171	reference genome using bwa-meth (github.com/brentp/bwa-meth). The generated bam
172	files were marked with duplication and merged if necessary. Estimation of the
173	duplication rate, coverage bias (genomic features) and methylation bias in reads was
174	carried out to provide quality control. All the metrics such as percentage of
	cannon our to provide damai, connon the months such as becomes of
175	unmapped/mapped read metrics, mapping quality distribution, GC content
175 176	unmapped/mapped read metrics, mapping quality distribution, GC content distribution, insert size distribution and coverage distribution were generated by
175 176 177	unmapped/mapped read metrics, mapping quality distribution, GC content distribution, insert size distribution and coverage distribution were generated by Qualimap 2 for further evaluation of the alignment. Finally, a count table and bigwig
175 176 177 178	unmapped/mapped read metrics, mapping quality distribution, GC content distribution, insert size distribution and coverage distribution were generated by Qualimap 2 for further evaluation of the alignment. Finally, a count table and bigwig files of methylated and coverage at each CpG site in the genome was constructed for

180 MethPipe ⁻ with count table of all samples as input. The analysis of differ
--

- 181 methylation and IR is described in the Supplementary Materials.
- 182
- 183 ChIP-seq data analysis
- 184 ChIP-seq data of histone modifications in K562 cells was retrieved from ENCODE
- 185 (encodeproject.org) and further processed as described in the Supplementary
- 186 Materials.
- 187
- 188 Statistical analyses
- 189 All statistical analyses were performed in R v.3.6.2. The Wald test implemented in the
- 190 R package $DESeq2^{25}$ was used for the identification of statistically significant
- 191 differential alternative splicing events, and differential gene expression analysis. P-
- values were adjusted for the false discovery rate using the Benjamini-Hochberg
- 193 procedure. Functional enrichment analysis of differentially expressed genes and genes
- 194 with differentially retained introns was performed using DAVID 6.7^{26} with the human
- 195 genome and the set of expressed genes, respectively, used as a background.

196

197 **Results**

- 198 The goal of our work was to evaluate transcriptomic and epigenetic changes in CML
- 199 patients after major or complete molecular response. We retrieved sixteen peripheral
- 200 blood samples of Philadelphia-positive (Ph+) CML patients. For 10 of these patients,
- 201 we also retrieved matched samples after remission. In addition, we retrieved
- 202 peripheral blood from six healthy donors (Table 1). We subjected all samples to RNA
- 203 sequencing and all matched diagnosis/remission samples as well as control samples to
- 204 WGBS.

205

206 Heterogeneous CML transcriptomes converge at remission

207	RNA sequencing reads mapping to the BCR-ABL1 locus were found in diagnosis
208	samples only (Supplementary Figure 2A), confirming the results of clinical qRT-
209	PCR-based BCR-ABL1 quantification (Supplementary Data 1). Apart from the
210	characteristic BCR-ABL1 fusion we identified other recurring intra- and inter-
211	chromosomal fusions (Supplementary Figure 2A&B Supplementary Data 2) that
212	occur in diagnosis, remission or control samples. A novel fusion transcript between
213	the myeloid cell-specific transmembrane glycoprotein CLEC12A (12p13.31) and the
214	microRNA miR-223 host gene MIR223HG (Xq12) was expressed at higher levels
215	(FC = 7.16) at diagnosis compared to remission (Supplementary Figure 2C&D).
216	For most patients we observed a global reduction of gene expression in remission
217	compared to diagnosis (Supplementary Figure 3A). This can be attributed to the
218	reconfigured blood cell composition, which resembles lymphoid cell-enriched normal
219	controls (Figure 1A&B). A significant downregulation was observed in genes
220	encoding kinases other than BCR-ABL1 and kinase-like proteins such as CENPE,
221	CDK1, AURKB, MELK, and BUB1B (Supplementary Figure 4). Reduced expression
222	at remission, similar to levels observed in control samples, also affected cyclins such
223	as CCNA1, CCNB2 and other cell cycle regulators as well as genes related to DNA
224	replication and repair (Figure 1A & Supplementary Figure 5A). In this context, no
225	consistent differences were noted between patients treated with imatinib or nilotinib
226	(Supplementary Figure 1).
227	A set of genes (n=81), that are functionally associated with oxygen and bicarbonate
228	transport (GO:0015671; GO:0015701) as well as the hemoglobin's chaperone

229 pathway (Biocarta), was significantly differentially expressed in all three comparisons

230 (diagnosis vs control, remission vs control, and diagnosis vs remission;

231 Supplementary Figure 5B). Overall, we observed that patients diagnosed with CML

232 have highly heterogeneous transcriptomes. In contrast, remission transcriptomes are

233 more alike (Figure 1C) and exhibit fewer differences in comparison to healthy control

234 samples (Supplementary Figure 3B).

235 DNA methylation profiles return to normal at remission

236 To characterise putative epigenetic causes for differential gene expression in CML

237 patients prior to and after successful TKI treatment, all matched diagnosis/remission

samples as well as all control samples were subjected to WGBS. The analysis

revealed almost 25,000 differentially methylated regions (DMRs) in the genomes of

240 diagnosis and remission samples (Figure 2A, left). Vast DNA methylome differences

241 were found in every matched patient sample (Supplementary Figure 6) and across all

chromosomes (Figure 2B). In contrast, only 710 DMRs were observed between

243 remission and control samples (Figure 2A, right). Indeed, multidimensional scaling

showed that DNA methylation profiles of remission samples are closer to those from

245 healthy donors rather than to matched diagnosis samples (Supplementary Figure 7).

246 DMRs between diagnosis and remission samples contain, on average, a larger number

247 of differentially methylated CpG sites (Figure 2C). This is consistent with previous

248 reports that suggest an increase in CpG site methylation during CML progression that

249 affects tumour-suppressor genes and regulators of cell proliferation¹⁰. DMRs are

associated with processes of the innate immune response, apoptosis, cell

251 differentiation, and cell migration (Figure 2D).

252 Our results show that DNA methylation returns to normal levels after successful TKI

treatment. Most DMRs can be found in intronic regions, however, the highest density

254	of DMRs was observed in 5' untranslated regions (Figure 2E), suggesting a key role
255	for differential DNA methylation in orchestrating CML gene expression regulation.
256	
257	Aberrant alternative splicing distinguishes remission samples from healthy
258	controls
259	To assess whether major or complete molecular remission also affects gene isoform
260	expression, we conducted a systematic analysis of the five major forms of alternative
261	splicing (Supplementary Figure 8A). In a pairwise comparison of alternative splicing
262	event frequencies between matched diagnosis/remission samples, no consistent trend
263	towards an increase or decrease in either of the two conditions was found
264	(Supplementary Figure 8B). This suggests, that in contrast to gene expression
265	profiles, splicing patterns remain atypical after major or complete molecular
266	remission.
267	Alternative splicing analysis of the Cancer Genome Atlas (TCGA) cohort by Dvinge
268	et al. (2015) revealed that the frequency of IR events is consistently higher in acute
269	myeloid leukemia compared to normal controls ⁸ . Although mean IR frequencies are
270	also higher in CML samples (diagnosis, $\bar{x} = 3382$; remission, $\bar{x} = 3484$) compared
271	to healthy donors ($\bar{x} = 2822$), high inter-donor variability led to differences in IR
272	frequencies that did not reach significance (Supplementary Figure 8C). However,
273	when we subsampled the RNA sequencing data to facilitate a uniform sequencing
274	depth for comparison, we observed a clear separation with significantly increased IR
275	frequencies at diagnosis and remission compared to controls (Supplementary Figure
276	9). Moreover, we found that the IR ratios are consistently higher in diagnosis and
277	remission samples compared to healthy controls (Figure 3A). Differences between
278	diagnosis and remission samples were less pronounced (Figure 3A; Supplementary

279	Figure 10). While IR profiles are unsuitable for patient stratification (Supplementary
280	Figure 11), differentially retained introns between diagnosis and remission samples
281	are, similarly to differentially expressed genes, associated with cell cycle regulators as
282	well as genes related to DNA replication and repair (Supplementary Figure 12).
283	However, in remission IR primarily affects genes involved in splicing processes
284	(Supplementary Figure 12) suggesting the aberrant splicing persists in remission due
285	to auto-regulatory processes. Overall, IR profiles are highly dynamic in CML, which
286	becomes apparent when considering the large overlap of differentially retained introns
287	(n = 419) in all three comparisons (Figure 3B). We confirmed these results with an
288	independent dataset of 59 CML patients from Branford et al. ⁹ , which includes
289	samples from various stages of disease progression, and from 4 healthy controls
290	(Figure 3C). The number of IR events in this cohort was highly variable. While there
291	are on average more IR events in chronic phase compared to healthy controls, the
292	number drops significantly at blast crisis (Figure 3C, right).
292 293	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend
292 293 294	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and
 292 293 294 295 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs)
 292 293 294 295 296 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%;
 292 293 294 295 296 297 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain
 292 293 294 295 296 297 298 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are
 292 293 294 295 296 297 298 299 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are associated with DNA repair mechanisms (top-enriched GO term; Figure 3E). Only 26
 292 293 294 295 296 297 298 299 300 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are associated with DNA repair mechanisms (top-enriched GO term; Figure 3E). Only 26 exons in total are differentially used in diagnosis vs remission samples (Figure 3D).
 292 293 294 295 296 297 298 299 300 301 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are associated with DNA repair mechanisms (top-enriched GO term; Figure 3E). Only 26 exons in total are differentially used in diagnosis vs remission samples (Figure 3D).
 292 293 294 295 296 297 298 299 300 301 302 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are associated with DNA repair mechanisms (top-enriched GO term; Figure 3E). Only 26 exons in total are differentially used in diagnosis vs remission samples (Figure 3D). <i>Modulation of IR levels supports lineage-specific gene expression in CML</i>
 292 293 294 295 296 297 298 299 300 301 302 303 	number drops significantly at blast crisis (Figure 3C, right). Examining differential exon usage in our samples we observed a similar trend although not as marked as observed in differential IR, i.e. both diagnosis and remission samples exhibit a larger number of differentially used exons (DUEs) compared to normal controls. Most of these DUEs are upregulated (diagnosis, 78%; remission, 81%; Figure 3D). A large fraction of the DUEs at diagnosis (72%) remain differentially expressed at remission as well. Some genes of these mutual DUEs are associated with DNA repair mechanisms (top-enriched GO term; Figure 3E). Only 26 exons in total are differentially used in diagnosis vs remission samples (Figure 3D). <i>Modulation of IR levels supports lineage-specific gene expression in CML</i> IR is accepted as a mechanism of post-transcriptional gene regulation triggering

305	the retained introns ^{27,28} . We analysed the relationship between IR and gene expression
306	changes but overall the two variables did not significantly correlate (Figure 4A).
307	However, many of the genes, whose expression does anti-correlate with the retention
308	of their introns, are involved in cell cycle regulation (e.g. CCL3, CKS2, and SPAG5),
309	and DNA replication/repair (e.g. FANCI/FANCD2, and PCNA) (Figure 4A).
310	We selected three differentially retained introns of cell cycle regulator genes for
311	experimental validation (CKS2 intron 1, CCL3 intron 1, and SERPINB1 intron 2).
312	Based on the RNA sequencing data analysis, all three introns have an increased
313	expression and higher IR ratio at diagnosis compared to healthy controls (Figure 4A).
314	We confirmed these observations via qRT-PCR (Figure 4B). The IR ratios of CKS2
315	intron 1, and SERPINB1 intron 2 increase further at remission resulting in a reduction
316	of host gene expression, while the IR ratio of CCL3 intron 1 is reduced at remission
317	and associated with an increase in gene expression (Figure 4A & B).
318	Interestingly, some instances of inverse relationships between IR and gene expression
319	affect lineage-specific genes (Figure 4C). For example, the chemokine Interleukin-8
320	(CXCL8), which is predominantly expressed in neutrophils, is upregulated at
321	diagnosis. This could be attributed to the increased myeloid progenitor cell abundance
322	(Figure 1B), but also to the reduced IR levels in CXCL8 mRNA (Figure 4A). In
323	control samples, the IR levels increase from 12.9% to 26.7% in CXCL8 (intron 2),
324	while gene expression is reduced 4-fold. CXCL8 promotes CML cell proliferation ²⁹
325	and previous reports suggest that CXCL8 expression is modulated both by BCR-ABL1
326	expression (causing increase) and TKI treatment (causing inhibition of $CXCL8$) ³⁰ .
327	In contrast, PRKCH is downregulated at CML diagnosis along with increased IR
328	levels (Figure 4A). <i>PRKCH</i> is a serine-threonine kinase that regulates hematopoietic
329	stem cell function and is specifically expressed in lymphoid cells. Notably, high

330 *PRKCH* expression has been associated with poor prognosis in acute myeloid

331 leukemia³¹.

332 These observations suggest that lineage-specific expression of drivers of cell

- 333 proliferation and hematopoietic cell differentiation can be mediated through IR level
- changes in CML.
- 335 *Epigenetic features modulate intron retention in CML*

336 Characteristics of the retained introns in our CML cohort are in accordance with

337 previously described attributes, such as their relatively short length (Supplementary

Figure 13), and higher GC content (Supplementary Figure 14). While these are

339 intrinsic features of IR, we sought potential *trans*-regulators and found that the gene

340 that most strongly correlates ($\rho = 0.64$) with IR frequencies is *MED21* (Mediator

341 Complex Subunit 21; Figure 5A). *MED21* regulates gene transcription by interacting

342 with RNA polymerase II^{32} . RNA polymerase II elongation rates influence splice site

343 recognition and IR^{13} . Interestingly, the expression of *ZNF160*, encoding a Zinc Finger

- Protein and repressor of transcription, strongly anti-correlates ($\rho = -0.62$) with IR
- 345 frequencies (Figure 5A).
- 346 We have previously shown that DNA methylation regulates IR in myeloid cells¹³. To

347 confirm this mode of regulation in our CML cohort, we compared CpG methylation

- around the splice sites (±200 bp) and in the centre (200 bp) of retained and non-
- retained introns. We confirmed decreased DNA methylation levels near the 3 splice
- 350 junction and within the body of retained introns (Figure 5B). Similar patterns were

351 observed in remission and control samples suggesting that this mode of IR regulation

is also present in lymphoid cells (Supplementary Figure 15).

353 To further investigate the role of epigenetics in the regulation of IR in CML, we

retrieved RNA-seq and ChIP-seq data of the K562 CML cell line from ENCODE. We

355	analysed transcriptomics data of RNA binding protein knockdown experiments and
356	observed significantly increased IR occurrences with the most drastic IR increase (~5
357	fold) following Poly(RC) Binding Protein 2 (PCBP2) knockdown (Figure 5C). All
358	genes with enriched binding motifs near frequently retained introns ²⁰ were
359	downregulated at CML diagnosis, except for SRSF5 (Supplementary Figure 16).
360	Three of these RNA binding proteins, including PCBP2, remained downregulated in
361	remission (Figure 5D).
362	To identify additional potential explanations for the dysregulation of IR in CML, we
363	analysed histone modifications in K562 cells. While higher levels of H3K36
364	trimethylation have previously been associated with IR ^{33,34} , we found only marginal
365	differences in H3K36me3 levels in retained versus non-retained introns. Increasing
366	numbers of H3K36me3 peaks around introns were observed in more highly expressed
367	genes (Supplementary Figure 17). However, we found that monomethylation and
368	acetylation of histone H3 lysines 4 and 9, respectively (H3K4me1 and H3K9ac) were
369	significantly enriched near splice sites of retained introns and within their intron
370	bodies in contrast to non-retained introns (Figure 5E). While a significant enrichment
371	of H3K9ac has been found to co-occur at many gene regulatory elements in mouse
372	embryonic stem cells ³⁵ , we here established a strong association of H3K9ac with IR.
373	Elevated levels of H3K4 methylation in association with IR have been previously
374	reported by Zhou et al. ³³ .
375	In summary, our analysis of CML patient transcriptomes revealed aberrant alternative
376	splicing both at diagnosis and remission. Elevated IR ratios in CML can be explained
377	by multiple regulatory mechanisms including the regulation of RNA Pol II
378	elongation, demethylation of CpG sites, and histone modifications (Figure 5F). The
379	TKI treatment itself seems to have no effect on IR (Supplementary Figure 18).

380

381 **Discussion**

382	In this study, we analysed epigenomics and transcriptomics data from patients
383	diagnosed with chronic phase Ph+ CML and matched remission samples after
384	effective treatment with TKIs. Thereby, we generated novel insights into the
385	molecular responses to TKI therapy beyond the known reduction in BCR-ABL1
386	expression.
387	We have identified recurring fusion transcripts in patient samples including an
388	uncharacterised fusion between the cell surface marker C-type lectin domain family
389	12 member A (CLEC12A; 12p13.31) and the MIR223 gene (Xq12). Other non-
390	specific intra-chromosomal fusions include EEF1DP3-FRY, EIF4E3-FOXP1,
391	KANSL1-ARL17B, and the mitochondrial fusion ND6-TE (Supplementary Figure 2A).
392	An increasing number of mitochondrial mutations and fusions have been described as
393	a consequence of increased reactive oxygen species during ageing ³⁶ , however, the age
394	range (21-70 yrs) of ND6-TE-positive patients in our cohort does not support an age-
395	related occurrence of this fusion.
396	Gene expression profiles of our CML remission samples are more similar to those of
397	healthy donors, likely due to the change in cell composition and the loss of BCR-
398	ABL1 clones. Consistent with previous studies, we found cell cycle regulators among
399	the most aberrantly expressed genes in the diagnosis samples. For example, cyclins
400	A1 and B2 (CCNA1, CCNB2) were among the most differentially expressed genes,
401	with overexpression at diagnosis and low expression at remission (comparable to
402	expression levels observed in healthy controls). While cyclin D2 (CCND2) has
403	previously been characterized as a BCR-ABL-dependent mediator of cell proliferation
404	in hematopoietic cells ³⁷ , marginal changes in CCND2 (FC= 0.87, p=.04) expression

405 suggest that other cyclins such as *CCNA1* (FC=12.3, p=5.4e-53) and *CCNB2*

406	(FC=7.2, p= 9.2e-55) were among the more potent regulators of cell proliferation in
407	this cohort of CML patients.

408	The most surprising results was that, in contrast to gene expression, alternative
409	splicing patterns did not return to normal in CML remission samples. Among other
410	forms of alternative splicing, IR affects transcriptomic complexity and leads to the
411	inclusion of premature termination codons in mature transcripts causing nonsense-
412	mediated decay ^{38,39,27,39,40} . Normal granulocytic blood cells make use of this
413	conserved mechanism of gene regulation by increasing the number of intron-retaining
414	transcripts of hundreds of genes that are essential to granulocytic differentiation ^{27,38} .
415	Shen et al. have shown that alternative splicing events can be used to construct
416	predictors for patient survival, that outperform gene expression-based predictors in
417	multiple cancers ⁴¹ . Splicing-based prognostic markers have already been found for
418	several cancer types ^{41,42} . Therefore, a splicing-based predictor for TKI cessation
419	success is not just desirable but an achievable prospect, once clinical data of trial TKI
420	cessation together with remission transcriptomics data become available.
421	Our results were consistent across patients and different specific TKI treatments. It is
422	known that the cell composition of the peripheral blood changes in CML - with
423	myeloid progenitor cell-enrichment at diagnosis and mature lymphoid cell-enrichment
424	at remission. The latter is very similar to the cell composition observed in the
425	peripheral blood of healthy individuals (Supplementary Figure 5). Therefore,
426	epigenomic and transcriptomic differences between diagnosis and remission may be
427	expected. However, remarkable are the persistent alternative splicing perturbations in
428	remission that do not resemble patterns observed in healthy controls.

429	We found new evidence for epigenetic regulators of alternative splicing, such as
430	reduced DNA methylation, and increased H3K4me1 and H3K9ac marks around
431	retained introns. We have previously shown that DNA methylation can regulate IR in
432	myeloid cells and during terminal granulopoiesis ^{13,43} . In CML reduced DNA
433	methylation in the intron body and $3\square$ splice site is associated with IR (Figure 5B). A
434	role for the promoter and enhancer mark H3K4 mono-methylation in gene repression
435	has been identified previously ⁴⁴ , however, H3K4me1-dependent alternative splicing
436	has not been described before. Both H3K4me1 and H3K9ac are present at the
437	promoters of intron-retaining and non-retaining genes but are predominantly found
438	near splice sites and within bodies of retained introns in contrast to non-retained
439	introns (Figure 5E). While both histone marks seem indicative of active transcription
440	(Figure 5E), by regulating Pol II recruitment and elongation rates ^{44,45} around splice
441	sites they could promote IR in CML. IR regulation via H3.3K36me3-specific readers,
442	such as previously shown in HeLa cells ³⁴ , seems less relevant in CML patients.

443 **Conclusions**

444 In summary, our study has provided new insights into the epigenomic and 445 transcriptomic landscapes of CML patients at diagnosis and remission. We have 446 shown that, despite a changing cell composition at major or complete molecular 447 remission, alternative splicing remains aberrantly regulated with high IR levels 448 affecting multiple cell cycle regulators. Further research is required to test whether 449 sustained RNA processing alterations in CML remission facilitate relapse following 450 TKI cessation. The new knowledge about epigenetic links to alternative splicing in 451 CML could facilitate the development of epigenetic therapeutic adjuvants to increase 452 the likelihood of successful TKI cessation. Modulation of spliceosome function has

- 453 recently been proposed as a new therapeutic avenue in leukemia⁴⁶, which is an idea
- 454 reinforced by our results.

455 List of abbreviations

- 456 CML chronic myeloid leukemia
- 457 DEU Differential exon usage
- 458 DUEs differentially used exons
- 459 DMRs Differentially methylated regions
- 460 FC fold change
- 461 GO gene ontology
- 462 IR intron retention
- 463 PBMCs peripheral blood mononuclear cells
- 464 Ph+ Philadelphia-positive
- 465 TCGA The Cancer Genome Atlas
- 466 TPM transcripts per million
- 467 TKI tyrosine kinase inhibitor
- 468 WGBS Whole genome bisulfite sequencing
- 469

470 **Declarations**

- 471 Ethics approval and consent to participate
- 472 All studies were approved by the institutional review boards (HREC protocol No:
- 473 131015, 070718c, 081211, and 101010 Royal Adelaide Hospital) and are in
- 474 accordance with the Declaration of Helsinki. Patients provided written informed
- 475 consent.

476 Consent for publication

- 477 Not applicable.
- 478 Availability of data and materials
- 479 The dataset supporting the conclusions of this article is available in the GEO
- 480 repository, <u>GSE144119</u>.

481 *Competing interests*

- 482 S.B. is member of the advisory board of Qiagen, Novartis and Cepheid, received
- 483 honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid, and research
- 484 support from Novartis. D.W. received RS funding and honoraria from BMS and
- 485 honoraria from Amgen. J.E.J.R. has received honoraria or speakers fees (GSK,
- 486 Miltenyi, Takeda, Gilead, Pfizer, Spark, Novartis, Celgene, bluebird bio); Director of
- 487 Pathology (Genea); equity ownership (Genea, Rarecyte); consultant (Rarecyte,
- 488 Imago); chair, Gene Technology Technical Advisory, OGTR, Australian
- 489 Government. The remaining authors declare no competing financial interests.
- 490 Funding
- 491 This work was supported by the National Health and Medical Research Council
- 492 (Investigator Grant #1177305 to J.E.J.R., Project #1128175 and #1129901 to J.E.J.R.
- 493 and J.J.-L.W., #1126306 to J.J.-L.W., APP1027531 and APP1104425 to S.B., and
- 494 APP1135949 to T.P.H.; the NSW Genomics Collaborative Grant (J.E.J.R. and J.J.-
- 495 L.W.); Cure the Future (J.E.J.R.); and an anonymous foundation (J.E.J.R.). U.S. and
- 496 J.J.-L.W. hold Fellowships from the Cancer Institute of New South Wales. U.S. also
- 497 received support from the Australian Academy of Science in form of an Australia-

- 498 India Early and Mid-Career Fellowship. Financial support was provided by Tour de
- 499 Cure (Scott Canner Research Fellowship) to C.G.B. and for research grants to C.G.B.
- 500 and J.E.J.R. This research was funded by the Cancer Council NSW Project Grants
- 501 (RG11-12, RG14-09, RG20-12) to J.E.J.R., C.G.B., and U.S. Support was also
- 502 received from the Ray and Shirl Norman Cancer Research Trust (S.B.).
- 503 Authors' contributions
- 504 J.E.J.R. and J.J.-L.W. designed the research. U.S., J.S.S., P.L.L., and V.P. performed
- 505 bioinformatic analyses and interpreted the data. D.L.W., V.A.S., S.B., A.G.T., and
- 506 T.P.H. provided CML patient samples, clinical data and further insight. B.D., G.M.,
- 507 S.N., C.M., and C.G.B. performed and/or supervised experiments. U.S. wrote the
- 508 manuscript with help from J.J.-L.W., J.S.S., G.M., B.D., and V.P. All authors
- 509 reviewed and approved the manuscript.
- 510 Acknowledgements
- 511 We would like to acknowledge Dr. Andreas Schreiber (University of South Australia)
- 512 for retrieving the sequencing data from the Branford et al. study⁹.
- 513
- 514

515 **References**

516 1. Peng C, Li S. Chronic Myeloid Leukemia (CML) Mouse Model in 517 Translational Research. *Methods Mol Biol.* 2016;1438:225-243. 518 2. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic 519 and cytogenetic responses in patients with accelerated phase chronic myeloid 520 leukemia: results of a phase 2 study. *Blood*. 2002;99(6):1928-1937. 521 3. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid 522 leukaemia. Lancet Oncol. 2007;8(11):1018-1029. 523 4. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: 524 mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254-2264. 525 Yong AS, Melo JV. The impact of gene profiling in chronic myeloid 5. 526 leukaemia. Best Pract Res Clin Haematol. 2009;22(2):181-190. 527 Ma W, Giles F, Zhang X, et al. Three novel alternative splicing mutations in 6. 528 BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int J Lab 529 Hematol. 2011;33(3):326-331. 530 7. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with 531 progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 532 2006;103(8):2794-2799. 533 8. Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer 534 transcriptomes. Genome Med. 2015;7(1):45. 535 9. Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals 536 cancer-associated mutations at diagnosis of CML in patients with high-risk disease. 537 Blood. 2018;132(9):948-961. 538 10. Heller G, Topakian T, Altenberger C, et al. Next-generation sequencing 539 identifies major DNA methylation changes during progression of Ph+ chronic 540 myeloid leukemia. Leukemia. 2016;30(9):1861-1868. 541 11. Wong ACH, Rasko JEJ, Wong JJ. We skip to work: alternative splicing in 542 normal and malignant myelopoiesis. Leukemia. 2018;32(5):1081-1093. 543 12. Tilgner H, Nikolaou C, Althammer S, et al. Nucleosome positioning as a 544 determinant of exon recognition. Nat Struct Mol Biol. 2009;16(9):996-1001. 545 13. Wong JJ, Gao D, Nguyen TV, et al. Intron retention is regulated by altered 546 MeCP2-mediated splicing factor recruitment. Nat Commun. 2017;8:15134. 547 Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq 14. 548 aligner. *Bioinformatics*. 2013;29(1):15-21. 549 15. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. 550 *Bioinformatics*. 2012;28(16):2184-2185. 551 16. Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis 552 results for multiple tools and samples in a single report. *Bioinformatics*. 553 2016;32(19):3047-3048. 554 17. Haas BJ, Dobin A, Stransky N, et al. STAR-Fusion: Fast and Accurate Fusion 555 Transcript Detection from RNA-Seq. bioRxiv. 2017:120295. 556 Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast 18. 557 and bias-aware quantification of transcript expression. Nature methods. 558 2017;14(4):417. 559 19. Shen S, Park JW, Lu ZX, et al. rMATS: robust and flexible detection of 560 differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci US 561 A. 2014;111(51):E5593-5601. 562 20. Middleton R, Gao D, Thomas A, et al. IRFinder: assessing the impact of 563 intron retention on mammalian gene expression. Genome Biol. 2017;18(1):51.

564 21. Anders S, Reyes A, Huber W. Detecting differential usage of exons from 565 RNA-seq data. Genome Res. 2012;22(10):2008-2017. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: 566 22. 567 bisulphite modification and analysis. *Nature protocols*. 2006;1(5):2353. 568 23. Nair SS, Luu PL, Qu W, et al. Guidelines for whole genome bisulphite 569 sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. *Epigenetics* 570 Chromatin. 2018;11(1):24. 571 Song Q, Decato B, Hong EE, et al. A reference methylome database and 24. 572 analysis pipeline to facilitate integrative and comparative epigenomics. *PLoS One*. 573 2013;8(12):e81148. 574 25. Love MI, Huber W, Anders S. Moderated estimation of fold change and 575 dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. 576 Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis 26. 577 of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-578 57. 579 27. Wong JJ, Ritchie W, Ebner OA, et al. Orchestrated intron retention regulates 580 normal granulocyte differentiation. Cell. 2013;154(3):583-595. 581 Edwards CR, Ritchie W, Wong JJ, et al. A dynamic intron retention program 28. 582 in the mammalian megakaryocyte and erythrocyte lineages. *Blood*. 2016;127(17):e24-583 e34. 584 29. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. 585 Exosome-mediated crosstalk between chronic myelogenous leukemia cells and 586 human bone marrow stromal cells triggers an interleukin 8-dependent survival of 587 leukemia cells. Cancer Lett. 2014;348(1-2):71-76. 588 30. Hantschel O, Gstoettenbauer A, Colinge J, et al. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic 589 590 myeloid leukemia. Mol Oncol. 2008;2(3):272-281. 591 31. Porter SN, Magee JA. PRKCH regulates hematopoietic stem cell function and 592 predicts poor prognosis in acute myeloid leukemia. *Exp Hematol.* 2017;53:43-47. 593 32. Plaschka C, Lariviere L, Wenzeck L, et al. Architecture of the RNA 594 polymerase II–Mediator core initiation complex. *Nature*. 2015;518(7539):376. 595 33. Zhou Y, Lu Y, Tian W. Epigenetic features are significantly associated with 596 alternative splicing. BMC Genomics. 2012;13:123. 597 34. Guo R, Zheng L, Park JW, et al. BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA 598 599 processing. Mol Cell. 2014;56(2):298-310. 600 Karmodiya K, Krebs AR, Oulad-Abdelghani M, Kimura H, Tora L. H3K9 and 35. 601 H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks 602 a subset of inactive inducible promoters in mouse embryonic stem cells. BMC 603 Genomics. 2012;13:424. 604 36. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat 605 *Rev Mol Cell Biol.* 2010;11(12):872-884. 606 37. Jena N, Deng M, Sicinska E, Sicinski P, Daley GQ. Critical role for cyclin D2 607 in BCR/ABL-induced proliferation of hematopoietic cells. *Cancer Res.* 608 2002;62(2):535-541. 609 38. Schmitz U, Pinello N, Jia F, et al. Intron retention enhances gene regulatory 610 complexity in vertebrates. *Genome Biol.* 2017;18(1):216. 611 Wong JJ, Au AY, Ritchie W, Rasko JE. Intron retention in mRNA: No longer 39. 612 nonsense: Known and putative roles of intron retention in normal and disease biology. 613 *Bioessays*. 2016;38(1):41-49.

- 614 40. Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans at a
- 615 glance. J Cell Sci. 2016;129(3):461-467.
- 616 41. Shen S, Wang Y, Wang C, Wu YN, Xing Y. SURVIV for survival analysis of
 617 mRNA isoform variation. *Nat Commun.* 2016;7:11548.
- 618 42. Li Y, Sun N, Lu Z, et al. Prognostic alternative mRNA splicing signature in
- non-small cell lung cancer. *Cancer Lett.* 2017;393:40-51.
- 620 43. Gao D, Pinello N, Nguyen TV, et al. DNA methylation/hydroxymethylation
- 621 regulate gene expression and alternative splicing during terminal granulopoiesis.
- 622 Epigenomics. 2019;11(1):95-109.
- 623 44. Cheng J, Blum R, Bowman C, et al. A role for H3K4 monomethylation in
- 624 gene repression and partitioning of chromatin readers. *Mol Cell*. 2014;53(6):979-992.
- 45. Gates LA, Shi J, Rohira AD, et al. Acetylation on histone H3 lysine 9
- 626 mediates a switch from transcription initiation to elongation. *J Biol Chem.*
- 627 2017;292(35):14456-14472.
- 628 46. Lee SC, Dvinge H, Kim E, et al. Modulation of splicing catalysis for
- 629 therapeutic targeting of leukemia with mutations in genes encoding spliceosomal
- 630 proteins. *Nat Med.* 2016;22(6):672-678.
- 47. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular
- heterogeneity landscape. *Genome Biol.* 2017;18(1):220.
- 48. Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for
- 634 comparative genomics. *Genome Res*. 2009;19(9):1639-1645.
- 635 49. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human
- 636 Protein Atlas. *Nat Biotechnol*. 2010;28(12):1248-1250.

638 Figure Legends

639	Figure 1 Molecular remission is reflected in transcriptomic profiles	. (A) The	То	p 200	differentially	v expressed
-----	--	------	-------	----	-------	----------------	-------------

- 640 genes with lowest adjusted *p*-value in likelihood ratio test. (B) Predicted cell type enrichment in peripheral blood
- 641 samples. The stacked bar graph shows normalized cell type enrichment scores for patient and control
- transcriptomes based on bulk RNA sequencing data. Predictions were made with the *xCell* R package
- 643 (github.com/dviraran/xCell)⁴⁷. HSC hematopoietic stem cell, CLP common lymphoid progenitor, CMP –
- 644 common myeloid progenitor, GMP granulocyte macrophage progenitor, MEP megakaryocytic erythroid
- 645 progenitor, NK natural killer, DC dendritic cell. (C) Principal component analysis separates diagnosis samples
- 646 from the common features of remission samples and healthy controls.
- 647
- 648 Figure 2 DNA methylation in CML. (A) Frequency of differentially methylated regions (DMRs) based on delta 649 values between pooled diagnosis and remission samples (left) as well as remission and control samples (right). (B) 650 Circos plot illustrating genome-wide differences in the frequency of DMRs (central ring with blue scatter plot: 651 diagnosis vs remission; inner ring with red scatterplot: remission vs control). This plot was generated using the 652 Circos software⁴⁸. (C) Scatterplot illustrating the number of significantly differentially methylated CpG sites per 653 DMR and associated delta values (red points, diagnosis vs remission; blue points, remission vs control). (D) 654 Enriched GO terms associated with DMRs (remission vs diagnosis) in gene promoter regions (red dashed line 655 marks p = 0.05). (E) Distribution and density of DMRs across gene features. RC – remission vs control; DR – 656 diagnosis vs remission; DC - diagnosis vs control.

658	Figure 3 Global alternative splicing patterns are similar despite major molecular remission. (A) Scatterplots
659	illustrating differential IR events between pooled diagnosis/remission/control samples binned into hexagons to
660	avoid overplotting (yellow: $p_{adj} \le 0.05$; red: $p_{adj} \le 0.01$). (B) Venn diagram showing intersections of
661	mutually differentially retained introns. (C) Dynamics of IR across CML phases. CML patient data from Branford
662	et al.9 was analysed for the occurrence of IR events. Left: Sample sizes for Control, CP: Chronic Phase, AP:
663	Accelerated Phase, MBC: Myeloid Blast Crisis, and LBC: Lymphoid Blast Crisis samples. Middle: Sample
664	numbers matched from different phases. Right: Boxplot of IR frequencies in samples from different CML phases.
665	Mann–Whitney U test; ** ($p < 0.01$), ns ($p > 0.05$). (D) Differential exon usage in pooled diagnosis vs control
666	(left), diagnosis vs remission (middle), and remission vs control samples. (E) Intersection of differentially used
667	exons in diagnosis and remission samples compared to controls (the top-enriched GO term and associated genes
668	are listed in the middle).

6	6	n
υ	υ	9

670	Figure 4 Differentially retained introns inhibit the expression of cell cycle regulators following major
671	molecular remission. (A) Scatterplots illustrating the relationship between differentially retained introns (Δ IR)
672	and differential gene expression (log2 expression fold change). Introns ($ \Delta IR \ge 0.1$) with inverse relationship to
673	host gene expression ($ log(FC) \ge 1$) are highlighted in red. (B) Coverage plots of selected differential IR events
674	(left) and qRT-PCR validation of differential IR between diagnosis and control (right). qRT-PCR validation was
675	performed in triplicates on independent diagnosis samples and results were normalised to B2M expression. D -
676	diagnosis; C - control. (C) Blood cell type expression of genes with inverse IR/gene expression relationships
677	(diagnosis v control; blue - myeloid, magenta - lymphoid cells). The data was retrieved from the Human Protein
678	Atlas (v19.3; http://www.proteinatlas.org) ⁴⁹ .

679

680	Figure 5 Regulation of IR in CML	(A) Two ger	es that most strong	v correlate/anti-correlate	with IR frequencies
000	rigure 5 Regulation of IR in CML	(\mathbf{A}) I wo get	es that most strong	y conclate/anti-conclate	, with include include

- 681 (Spearman correlation). (B) CpG methylation around intron splice sites (±200 bp) and in the centre (200 bp) of
- retained- (red) and non-retained introns (blue) in CML diagnosis samples. General linear hypothesis test; p-value <
- 683 2.2e-16 (adj.-p < 1e-10). (C) The effect of RNA binding proteins on IR frequency. RNA-seq data of shRNA-
- 684 mediated knockdown of indicated RNA binding proteins in K562 cells was retrieved from the ENCODE project
- 685 (encodeproject.org). WT wild type. (D) Expression of RNA binding proteins with enriched binding motifs near
- 686 frequently retained introns²⁰. TPM transcripts per million mapped reads; C control; D diagnosis; R -
- 687 remission; n.s. non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001. (E) Histone modifications with increased
- numbers of peaks near splice sites of retained introns (red: retained; blue: non-retained introns). The analysis was
- 689 repeated for each expression quartile to exclude the possibility that increased histone modifications are associated
- 690 with gene expression. (F) Possible mechanisms of IR regulation in CML discussed in the text.

692 Tables

- 693 Table 1 Patient and healthy donor samples used in RNAseq and WGBS experiments. Sequencing was
- 694 performed on PBMCs.

	Diagnosis	Remission	Control
Number of samples	16	11	6
Sex (F/M)	11/5	8/3	2/4
Median age yrs (range)	54 (21-69)	56 (23-70)	37 (30-42)
Trial (RESIST/ENESTxtnd/PINNACLE/	1/4/4/7	1/4/4/2	
PERSISTEM)			
Timepoint	Screening (x12)	6-35 months	
	/Day1		_
First line TKI (imatinib/nilotinib)	8	_	
RNAseq and WGBS (RNAseq only)	10 (+6)	10 (+1)	6

⁶⁹⁵

Figure 1



Figure 2





D

Innate immune response Neg. regul. of thymocyte apoptotic process-Positive regulation of T cell differentiation-Cell migration







Figure 4



Figure 5

